Clinical Trials

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07479979 2026-03-18

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT05434689 2026-03-05

COMMANDER

80 enrolled

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT04973605 2026-02-20

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

246 enrolled

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

17 enrolled

Multiple Myeloma

NCT05199311 2026-02-18

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

66 enrolled

Multiple Myeloma

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

440 enrolled

Multiple Myeloma, Neoplasms

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT06055075 2025-07-14

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

19 enrolled

Multiple Myeloma, Recurrence

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled

Multiple Myeloma, Recurrence

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02773030 2024-06-25

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

466 enrolled

Multiple Myeloma, Recurrence

NCT02073097 2024-05-29

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

48 enrolled 18 charts

Lymphoma, Large B-Cell, Diffuse

NCT01941316 2024-05-09

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

GastrointestinalGynecologicThoracic

78 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT03201250 2023-09-08

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

11 enrolled 11 charts

Multiple Myeloma

NCT02204241 2023-07-03

CCD

36 enrolled

Disease, Multiple Myeloma

NCT01677858 2022-09-23

CHAMPION 1

116 enrolled 28 charts

Multiple Myeloma

NCT05060627 2022-09-08

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

60 enrolled

Multiple Myeloma

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

136 enrolled

Multiple Myeloma

NCT03141203 2022-05-18

RomiCar

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

LymphoidOther hematologic neoplasmPlasma cell

53 enrolled 17 charts

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

14 enrolled 9 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03795597 2021-04-26

BuMelCarAuto

Phase 1/2 Unknown

36 enrolled

Multiple Myeloma

NCT02545907 2021-04-15

CATALYST

10 enrolled 14 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01842308 2020-09-01

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

50 enrolled 14 charts

Multiple Myeloma

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

83 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT01690143 2018-08-07

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

45 enrolled 10 charts

Multiple Myeloma

NCT01987232 2017-08-28

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

32 enrolled 18 charts

Thoracic

Small Cell Lung Carcinoma

NCT00531284 2017-08-15

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

GenitourinaryGynecologicLymphoidPlasma cellThoracic

184 enrolled 36 charts

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Lymphoma, Multiple Myeloma, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02802163 2017-04-25

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Phase 1/2 Withdrawn

Multiple Myeloma

NCT01279694 2016-04-13

CARMYSAP

72 enrolled